35.00

0.28% -0.10

Pre-market: 35.50 0.50 +1.43%

Structure Therapeutics Inc Adr (GPCR)

Overview News Price History Option Chain Financials Why GPCR Down? Discussions Forecast

Structure Therapeutics Inc Adr stock is traded at $35.00, with a volume of 1.53M. It is down -0.28% in the last 24 hours and down -34.62% over the past month. Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Previous Close:

$35.10

Open:

$35.04

24h Volume:

1.53M

Relative Volume:

1.99

Market Cap:

$2.50B

Revenue:

Net Income/Loss:

$-170.73M

P/E Ratio:

-13.00

EPS:

-2.6921

Net Cash Flow:

$-159.70M

1W Performance:

-9.47%

1M Performance:

-34.62%

6M Performance:

-32.55%

1Y Performance:

+50.67%

1-Day Range:

$34.41

$35.63

1-Week Range:

$34.41

$39.24

52-Week Range:

$22.70

$94.90

Structure Therapeutics Inc Adr Stock (GPCR) Company Profile

Name

Structure Therapeutics Inc Adr

Sector

Healthcare (1065)

Industry

Biotechnology (594)

Phone

(650) 457-1978

Address

601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO

Employee

233

Twitter

Next Earnings Date

2026-11-05

Latest SEC Filings

GPCR's Discussions on Twitter

Compare GPCR vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GPCR Structure Therapeutics Inc Adr	35.00	2.76B	0	-170.73M	-159.70M	-2.6921
VRTX Vertex Pharmaceuticals Inc	508.34	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	784.85	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.32	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	154.04	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	190.95	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	Canaccord Genuity	Buy
Mar-26-26	Initiated	Wolfe Research	Peer Perform
May-02-25	Initiated	Citigroup	Buy
Feb-28-25	Initiated	William Blair	Outperform
Jan-08-25	Initiated	Stifel	Buy
Dec-04-24	Initiated	H.C. Wainwright	Buy
Sep-23-24	Initiated	Morgan Stanley	Overweight
May-21-24	Initiated	JP Morgan	Overweight
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	JMP Securities	Mkt Outperform
Jul-27-23	Initiated	Piper Sandler	Overweight
May-25-23	Resumed	Jefferies	Buy
Feb-28-23	Initiated	BMO Capital Markets	Outperform
Feb-28-23	Initiated	Guggenheim	Buy
Feb-28-23	Initiated	Jefferies	Buy
Feb-28-23	Initiated	SVB Securities	Outperform

View All

Structure Therapeutics Inc Adr Stock (GPCR) Latest News

Sep 11, 2026

Price-Driven Insight from (GPCR) for Rule-Based Strategy - Stock Traders Daily

Sep 11, 2026

Sep 10, 2026

Structure Therapeutics at Cantor conference: oral obesity push advances By Investing.com - Investing.com Canada

Sep 10, 2026

Structure Therapeutics at Cantor conference: oral obesity push advances - Investing.com

Sep 10, 2026

Sep 09, 2026

Structure Therapeutics Advances ACCG-2671 with 3.3% Weight Loss; Aleniglipron Hits 16.2% Reduction (NASDAQ: GPCR) - Kalkine Media

Sep 09, 2026

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail

Sep 09, 2026

Structure Therapeutics stock price target maintained at $70 by H.C. Wainwright - Investing.com Canada

Sep 09, 2026

Citizens reiterates Structure Therapeutics stock rating on trial data - investing.com

Sep 09, 2026

Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada

Sep 09, 2026

Sep 08, 2026

Structure Therapeutics (GPCR) Shares Slide After Obesity Drug Tr - GuruFocus

Sep 08, 2026

Jefferies raises Structure Therapeutics stock target on amylin data By Investing.com - Investing.com Canada

Sep 08, 2026

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study - Zacks Investment Research

Sep 08, 2026

Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results - TipRanks

Sep 08, 2026

Oral obesity drug shows double-digit weight loss as Structure Therapeutics (NASDAQ: GPCR) advances Phase 3 trials - Stock Titan

Sep 08, 2026

A weight-loss pill cut body weight 16.2% in 72 weeks - Stock Titan

Sep 08, 2026

Sep 03, 2026

Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com

Sep 03, 2026

Morgan Stanley’s conference is one of three Structure Therapeutics plans to join in September - Stock Titan

Sep 03, 2026

Sep 02, 2026

Structure Therapeutics (GPCR) CSO sells 5,939 ADSs under preset plan - stocktitan.net

Sep 02, 2026

Aug 31, 2026

(GPCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Aug 31, 2026

Aug 26, 2026

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? - Eastern Progress

Aug 26, 2026

Aug 25, 2026

Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - The Globe and Mail

Aug 25, 2026

Aug 20, 2026

Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? - Eastern Progress

Aug 20, 2026

Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat

Aug 20, 2026

Aug 19, 2026

Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan

Aug 19, 2026

How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView

Aug 19, 2026

Aug 18, 2026